Visp\u0101r\u012bgie farmaceitiskie prakses vadl\u012bnijas atbilsto\u0161ai ar liofiliz\u0113tiem pept\u012bdiem r\u012bko\u0161an\u0101s attiecas uz CJC-1295. Tom\u0113r zin\u0101tniskaj\u0101 literat\u016br\u0101, kas tika p\u0101rskat\u012bta \u0161ai s\u0113rijai, nav identific\u0113ts neviens neatkar\u012bgi public\u0113ts, public\u0113ts p\u0113t\u012bjums par \u0161\u012b savienojuma stabilit\u0101ti. Tas noz\u012bm\u0113, ka konkr\u0113tie glab\u0101\u0161anas laika skait\u013ci, kas bie\u017ei redzami tie\u0161saist\u0113 \u2014 piem\u0113ram, \u201eizlietot 7\u201314 dienu laik\u0101\u201d vai \u201estabils 28 dienas\u201d \u2014 n\u0101k no ra\u017eot\u0101ja vai p\u0101rdev\u0113ja vadl\u012bnij\u0101m, nevis no public\u0113tiem, neatkar\u012bgi p\u0101rbaud\u012btiem p\u0113t\u012bjumiem. \u0160\u012b nianse tiek pien\u0101c\u012bgi izmantota vis\u0101 \u0161aj\u0101 rakst\u0101.<\/p>\n
CJC-1295, l\u012bdz\u012bgi k\u0101 liel\u0101k\u0101 da\u013ca pept\u012bdu, tiek pieg\u0101d\u0101ts k\u0101 liofiliz\u0113ts pulveris. Tas ir t\u0101p\u0113c, ka \u0161is sausais, pulverveida st\u0101voklis parasti ir \u0137\u012bmiski stabil\u0101ks nek\u0101 pept\u012bds, kas jau ir iz\u0161\u0137\u012bdin\u0101ts \u0161\u0137idrum\u0101. Faktiski \u0161\u012b saus\u0101 pulvera forma ir visilg\u0101k dokument\u0113t\u0101 uzglab\u0101\u0161anas stabilit\u0101te starp vis\u0101m form\u0101m, ko savienojums pie\u0146em. Visp\u0101r\u0113j\u0101 vislab\u0101k\u0101 prakse attiec\u012bb\u0101 uz liofiliz\u0113tiem pept\u012bdiem, kas ir konsekventa vis\u0101 farm\u0101cijas un laboratoriju nozar\u0113, ir diezgan vienk\u0101r\u0161a. Neatv\u0113rtu pulveri uzglab\u0101jiet v\u0113s\u0101, saus\u0101, tum\u0161\u0101 viet\u0101, kas pasarg\u0101ta no gaismas un mitruma. Pieg\u0101d\u0101t\u0101ju un laboratorijas darba avoti parasti iesaka uzglab\u0101t sald\u0113tav\u0101 \u2013 apm\u0113ram -20\u00b0C vai aukst\u0101k \u2013 lai nodro\u0161in\u0101tu visilg\u0101ko iesp\u0113jamo glab\u0101\u0161anas laiku neuzmais\u012btam pulverim.<\/p>\n
Kad pulveris ir sajaukts ar \u0161\u0137idrumu (process, ko sauc par rekonstit\u016bciju), tiek piem\u0113roti citi noteikumi. Visp\u0101r\u0113j\u0101 farmaceitisk\u0101 prakse \u2013 t\u0101ds pats princips, ko piem\u0113ro daudziem injic\u0113jamiem pept\u012bdu un prote\u012bnu produktiem, piem\u0113ram, insul\u012bnam \u2013 nosaka, ka ieg\u016btais \u0161\u0137\u012bdums j\u0101glab\u0101 ledusskap\u012b, parasti temperat\u016br\u0101 no 2 l\u012bdz 8\u00b0C, un to nedr\u012bkst atst\u0101t istabas temperat\u016br\u0101. Tas ir t\u0101p\u0113c, ka iz\u0161\u0137\u012bdin\u0101tie pept\u012bdi parasti ir jut\u012bg\u0101ki pret karstumu, gaismu un laika ietekmi nek\u0101 to liofiliz\u0113tie kol\u0113\u0123i.<\/p>\n
Ir v\u0113rts b\u016bt tie\u0161iem. \u0160\u012bs uzglab\u0101\u0161anas prakses atspogu\u013co visp\u0101r\u012bgos, labi iesak\u0146oju\u0161os principus pept\u012bdu k\u0101 kategorijas apstr\u0101dei, kas konsekventi atk\u0101rtoti komerci\u0101lo un laboratoriju pieg\u0101d\u0101t\u0101ju vadl\u012bnij\u0101s. \u0160ie nav atkl\u0101jumi no \u012bpa\u0161a, neatkar\u012bgi public\u0113ta stabilit\u0101tes p\u0113t\u012bjuma, kas \u012bpa\u0161i m\u0113ra, k\u0101 CJC-1295 sadal\u0101s kontrol\u0113tos apst\u0101k\u013cos.<\/p>\n
\u0160\u012b ir joma, kur\u0101 j\u0101iev\u0113ro visliel\u0101k\u0101 piesardz\u012bba. Komerc- un laboratorijas avoti bie\u017ei min, ka rekonstitucion\u0113tais CJC-1295, atdzes\u0113ts, saglab\u0101jas stabils no vienas l\u012bdz \u010detr\u0101m ned\u0113\u013c\u0101m, lai gan da\u017e\u0101di avoti sniedz at\u0161\u0137ir\u012bgus konkr\u0113tus skait\u013cus \u0161aj\u0101 visp\u0101r\u012bgaj\u0101 diapazon\u0101. \u0160iem skait\u013ciem vajadz\u0113tu b\u016bt saprotamiem k\u0101 ra\u017eot\u0101ja vai p\u0101rdev\u0113ja nor\u0101d\u012bjumiem un visp\u0101r\u0113jo nozares konvenciju \u2013 nevis k\u0101 neatkar\u012bgi veikta, recenz\u0113ta stabilit\u0101tes p\u0113t\u012bjuma atkl\u0101jumiem. Zin\u0101tniskaj\u0101 literat\u016br\u0101, kas tika p\u0101rskat\u012bta \u0161ai s\u0113rijai, nav atrasts neviens public\u0113ts p\u0113t\u012bjums, kas m\u0113r\u012btu faktisko CJC-1295 sadal\u012b\u0161an\u0101s \u0101trumu laika gait\u0101 p\u0113c sajauk\u0161anas.<\/p>\n
Tas ir b\u016btisks j\u0113dziens, kas j\u0101izprot. P\u0101rdev\u0113ja nor\u0101d\u012btais der\u012bguma termi\u0146\u0161 vi\u0146a pa\u0161a produkta lap\u0101 nav tas pats, kas kontrol\u0113ts laboratorijas p\u0113t\u012bjums, kas m\u0113ra, cik daudz neboj\u0101ta pept\u012bda faktiski paliek noteiktos laika punktos p\u0113c sajauk\u0161anas. \u0160\u0101ds stingr\u0101ks neatkar\u012bgas p\u0101rbaudes veids \u0161\u0137iet v\u0113l neeksist\u0113 eso\u0161aj\u0101 publik\u0101cij\u0101 par \u0161o konkr\u0113to savienojumu.<\/p>\n
\u0145emot v\u0113r\u0101 \u0161o nepiln\u012bbu, \u0161aj\u0101 rakst\u0101 netiks sniegts viens konkr\u0113ts skaitlis k\u0101 zin\u0101tniski apstiprin\u0101ts fakts. Prec\u012bzi var teikt tikai \u0161\u0101di: rekonstitu\u0113ti pept\u012bdi kopum\u0101 tiek uzskat\u012bti par \u0101tr\u0101k sadalo\u0161iemies nek\u0101 to saus\u0101 pulvera veid\u0101, un dzes\u0113\u0161ana konsekventi tiek ieteikta, nevis uzglab\u0101\u0161ana istabas temperat\u016br\u0101, tikl\u012bdz pept\u012bds ir iz\u0161\u0137\u012bdin\u0101ts.<\/p>\n
Savas nemais\u012bt\u0101, liofiliz\u0113t\u0101 pulvera veid\u0101 daudzi pept\u012bdi var iztur\u0113t ierobe\u017eotus laika periodus istabas temperat\u016br\u0101 bez iev\u0113rojama sadal\u012b\u0161an\u0101s. Tom\u0113r sald\u0113tavas vai ledusskapja uzglab\u0101\u0161ana joproj\u0101m parasti ir ieteikta ra\u017eot\u0101ju un laboratorijas rokasgr\u0101mat\u0101s, lai maksim\u0101li palielin\u0101tu saus\u0101 pulvera ilgtermi\u0146a stabilit\u0101ti, \u012bpa\u0161i ilgsto\u0161ai uzglab\u0101\u0161anai, kas m\u0113r\u0101ma m\u0113ne\u0161os. Tikl\u012bdz tas tiek sajaukts \u0161\u0137idr\u0101 \u0161\u0137\u012bdum\u0101, vadl\u012bnijas main\u0101s. Dzes\u0113\u0161ana k\u013c\u016bst svar\u012bga, nevis izv\u0113les iesp\u0113ja. Iz\u0161\u0137\u012bdin\u0101tie pept\u012bdi ir \u0137\u012bmiski akt\u012bv\u0101ki un vair\u0101k pak\u013cauti sadal\u012b\u0161anai no istabas temperat\u016bras, gaismas iedarb\u012bbas un atk\u0101rtotas apstr\u0101des.<\/p>\n
Attiec\u012bb\u0101 uz konkr\u0113tu jaut\u0101jumu par rekonstru\u0113ta \u0161\u0137\u012bduma sasald\u0113\u0161anu, visp\u0101r\u012bg\u0101s laboratorisk\u0101s prakses vadl\u012bnijas bie\u017ei vien neiesaka atk\u0101rtotus sasald\u0113\u0161anas-atkusin\u0101\u0161anas ciklus. \u0160\u0137idra \u0161\u0137\u012bduma sasald\u0113\u0161anas un atk-u\u0161in\u0101\u0161anas fizik\u0101lais process var potenci\u0101li izjaukt pept\u012bda strukt\u016bru. Tas notiek, veidojoties ledus krist\u0101liem un radot meh\u0101nisku stresu molekulai. Atkal, \u0161is ir pla\u0161i piem\u0113rojams princips pept\u012bdu apstr\u0101d\u0113, nevis atkl\u0101jums no \u012bpa\u0161a p\u0113t\u012bjuma par CJC-1295 sasald\u0113\u0161anu-atk-u\u0161in\u0101\u0161anu.<\/p>\n
T\u0101pat k\u0101 ar iepriek\u0161 min\u0113tajiem stabilit\u0101tes numuriem, \u0161ie uzglab\u0101\u0161anas ieteikumi ir konsekventi un sapr\u0101t\u012bgi farmaceitisk\u0101s zin\u0101tnes visp\u0101r\u012bgo principu pielietojumi. Tom\u0113r tie p\u0101rst\u0101v ra\u017eot\u0101ja un laboratorijas konvenciju vadl\u012bnijas, nevis neatkar\u012bgi public\u0113tus, recenz\u0113tus p\u0113t\u012bjumus, kas ir specifiski saist\u012bti ar \u0161o savienojumu.<\/p>\n
\u0160aj\u0101 rakst\u0101 sniegt\u0101s vadl\u012bnijas par uzglab\u0101\u0161anu un stabilit\u0101ti ir balst\u012btas uz labi nostiprin\u0101tiem, visp\u0101r\u012bgiem pept\u012bdu zin\u0101tnes principiem. Sausi, liofiliz\u0113ti pept\u012bdi ir stabil\u0101ki nek\u0101 iz\u0161\u0137\u012bdin\u0101tie. Dzes\u0113\u0161ana pal\u0113nina atjaunoto \u0161\u0137\u012bdumu sadal\u012b\u0161anos. Un atk\u0101rtotas sasal\u0161anas-atsald\u0113\u0161anas cikli parasti tiek neieteikti. Tom\u0113r nekas no iepriek\u0161 min\u0113t\u0101 nav ieg\u016bts no \u012bpa\u0161a, neatkar\u012bgi public\u0113ta stabilit\u0101tes p\u0113t\u012bjuma, kas veikts tie\u0161i CJC-1295.<\/p>\n
Komerci\u0101lie un laboratorijas avoti bie\u017ei atsaucies uz konkr\u0113tiem stabilit\u0101tes periodiem, da\u017ek\u0101rt vienam l\u012bdz \u010detr\u0101m ned\u0113\u013c\u0101m, uzglab\u0101jot v\u0113s\u0101. Tom\u0113r \u0161ie skait\u013ci b\u016btu j\u0101saprot k\u0101 ra\u017eot\u0101ja vai pieg\u0101d\u0101t\u0101ja pras\u012bbas un visp\u0101r pie\u0146emta nozares prakse; nevis k\u0101 apstiprin\u0101ti atkl\u0101jumi no neatkar\u012bgiem, recenz\u0113tiem anal\u012btiskiem p\u0113t\u012bjumiem. Nek\u0101di t\u0101di p\u0113t\u012bjumi netika identific\u0113ti zin\u0101tniskaj\u0101 literat\u016br\u0101, kas tika p\u0101rskat\u012bta \u0161ai s\u0113rijai.<\/p>\n
\u0160is saturs ir paredz\u0113ts tikai izgl\u012btojo\u0161iem un informat\u012bviem nol\u016bkiem, un to nevajadz\u0113tu interpret\u0113t k\u0101 medic\u012bnisku padomu vai apstiprin\u0101tu uzglab\u0101\u0161anas instrukciju. CJC-1295 joproj\u0101m ir p\u0113tniec\u012bbas savienojums, un to nav apstiprin\u0101jusi FDA vai Eiropas Z\u0101\u013cu a\u0123ent\u016bra nevienam medic\u012bniski lieto\u0161anai. \u0160eit sniegt\u0101s uzglab\u0101\u0161anas vadl\u012bnijas atspogu\u013co visp\u0101r\u012bgus, labi izveidotus principus pept\u012bdu apstr\u0101dei, nevis \u012bpa\u0161u stabilit\u0101tes p\u0113t\u012bjumu, kas veikts tie\u0161i \u0161im savienojumam. Konkr\u0113ti komerci\u0101li izplat\u012btie glab\u0101\u0161anas laika skait\u013ci nav neatkar\u012bgi p\u0101rbaud\u012bti, veicot public\u0113tus p\u0113t\u012bjumus.<\/p>","protected":false},"excerpt":{"rendered":"
Visp\u0101r\u012bgie farmaceitiskie noteikumi par r\u012bc\u012bbu ar liofiliz\u0113tiem pept\u012bdiem attiecas uz CJC-1295. Tom\u0113r nav veikts neviens neatkar\u012bgi public\u0113ts, recenz\u0113ts stabilit\u0101tes p\u0113t\u012bjums, kas b\u016btu specifisks \u0161im savienojumam\u2026<\/p>","protected":false},"author":7908,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[245],"tags":[],"class_list":["post-52581","post","type-post","status-publish","format-standard","hentry","category-kategoria-cjc1295-ipamorelin","beh-no-thumb"],"_links":{"self":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts\/52581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/users\/7908"}],"replies":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/comments?post=52581"}],"version-history":[{"count":0,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts\/52581\/revisions"}],"wp:attachment":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/media?parent=52581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/categories?post=52581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/tags?post=52581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}